Serum resistin: A biomarker of breast cancer in postmenopausal women? Association with clinicopathological characteristics, tumor markers, inflammatory and metabolic parameters

Clinical Biochemistry

Volumn 46, Issue 7-8, 2013, Pages 584-590

  Dalamaga, Maria ^a,b   Sotiropoulos, George ^c   Karmaniolas, Konstantinos ^d   Pelekanos, Nicolaos ^a   Papadavid, Evangelia ^a   Lekka, Antigoni ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

^c ATHENS NAVAL HOSPITAL   (Greece)

^d NIMTS HOSPITAL   (Greece)

Author keywords

Adipokine; Biomarker; Breast cancer; Inflammation; Postmenopausal; Resistin

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; HORMONE RECEPTOR; INTERLEUKIN 6; RESISTIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR MARKER;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BLOOD LEVEL; BREAST CANCER; BREAST LESION; CANCER DIAGNOSIS; CANCER GRADING; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; CYTOPATHOLOGY; DISEASE MARKER; FEMALE; HUMAN; INFLAMMATORY PARAMETER; MAJOR CLINICAL STUDY; METABOLIC PARAMETERS; MIDDLE AGED; PARAMETERS; POSTMENOPAUSE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; TUMOR INVASION; TUMOR VOLUME; AGED; BLOOD; BREAST TUMOR; METABOLISM; OBESITY; PATHOLOGY;

AGED; BREAST NEOPLASMS; C-REACTIVE PROTEIN; FEMALE; HUMANS; INTERLEUKIN-6; MIDDLE AGED; OBESITY; POSTMENOPAUSE; RESISTIN; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84884738926     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2013.01.001     Document Type: Article

References (33)

1. Vogel V.G. Epidemiology, genetics, and risk evaluation of postmenopausal women at risk of breast cancer. Menopause 2008, 15:782-789.
2. Zaman K., Bodmer A., Pralong F., Castiglione-Gertsch M. Breast cancer and obesity, a dangerous relation. Rev Med Suisse 2012, 8:1101-1104.
3. Dalamaga M., Archondakis S., Sotiropoulos G., Karmaniolas K., Pelekanos N., Papadavid E., et al. Could serum visfatin be a potential biomarker for postmenopausal breast cancer?. Maturitas 2012, 71:301-308.
4. La Vecchia C., Giordano S.H., Hortobagyi G.N., Chabner B. Overweight, obesity, diabetes, and risk of breast cancer: interlocking pieces of the puzzle. Oncologist 2011, 16:726-729.
5. Dalamaga M. Nicotinamide phosphoribosyl-transferase/visfatin: a missing link between overweight/obesity and postmenopausal breast cancer? Potential preventive and therapeutic perspectives and challenges. Med Hypotheses 2012, 79:617-621.
6. Mantzoros C., Petridou E., Dessypris N., Chavelas C., Dalamaga M., Alexe D.M., et al. Adiponectin and breast cancer risk. J Clin Endocrinol Metab 2004, 89:1102-1107.
7. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005, 115:911-919.
8. Dalamaga M., Diakopoulos K.N., Mantzoros C.S. The role of adiponectin in cancer: a review of current evidence. Endocr Rev 2012, 33:547-594.
9. Filkova M., Haluzik M., Gay S., Senolt L. The role of resistin as a regulator of inflammation: implications for various human pathologies. Clin Immunol 2009, 133:157-170.
10. Kang J.H., Yu B.Y., Youn D.S. Relationship of serum adiponectin and resistin levels with breast cancer risk. J Korean Med Sci 2007, 22:117-121.
11. Hou W.K., Xu Y.X., Yu T., Zhang L., Zhang W.W., Fu C.L., et al. Adipocytokines and breast cancer risk. Chin Med J 2007, 120:1592-1596.
12. Sun C.A., Wu M.H., Chu C.H., Chou Y.C., Hsu G.C., Yang T., et al. Adipocytokine resistin and breast cancer risk. Breast Cancer Res Treat 2010, 123:869-876.
13. Gaudet M.M., Falk R.T., Gierach G.L., Jr Lacey J.V., GraubardI B.I., Dorgan J.F., et al. Do adipokines underlie the association between known risk factors and breast cancer among a cohort of United States women?. Cancer Epidemiol 2010, 34:580-586.
14. Nakajima T.E., Yamada Y., Hamano T., Furuta K., Gotoda T., Katai H., et al. Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer. J Gastroenterol 2009, 44:685-690.
15. Nakajima T.E., Yamada Y., Hamano T., Furuta K., Matsuda T., Fujita S., et al. Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci 2010, 101:1286-1291.
16. Kumor A., Daniel P., Pietruczuk M., Małecka-Panas E. Serum leptin, adiponectin, and resistin concentration in colorectal adenoma and carcinoma (CC) patients. Int J Colorectal Dis 2009, 24:275-281.
17. Danese E., Montagnana M., Minicozzi A.M., Bonafini S., Ruzzenente O., Gelati M., et al. The role of resistin in colorectal cancer. Clin Chim Acta 2012, 413:760-764.
18. Hlavna M., Kohut L., Lipkova J., Bienertova-Vasku J., Dostalova Z., Chovanec J., et al. Relationship of resistin levels with endometrial cancer risk. Neoplasma 2011, 58:124-128.
19. Dalamaga M., Karmaniolas K., Panagiotou A., Hsi A., Chamberland J., Dimas C., et al. Low circulating adiponectin and resistin, but not leptin, levels are associated with multiple myeloma risk: a case-control study. Cancer Causes Control 2009, 20:193-199.
20. Dalamaga M., Karmaniolas K., Nikolaidou A., Chamberland J., Hsi A., Dionyssiou-Asteriou A., et al. Adiponectin and resistin are associated with risk for myelodysplastic syndrome, independently from the insulin-like growth factor-I (IGF-I) system. Eur J Cancer 2008, 44:1744-1753.
21. Pamuk G.E., Demir M., Harmandar F., Yesil Y., Turgut B., Vural O. Leptin and resistin levels in serum of patients with hematologic malignancies: correlation with clinical characteristic. Exp Oncol 2006, 28:241-244.
22. Nakajima T.E., Yamada Y., Hamano T., Furuta K., Oda I., Kato H., et al. Adipocytokines and squamous cell carcinoma of the esophagus. J Cancer Res Clin Oncol 2010, 136:261-266.
23. Lee Y.C., Chen Y.J., Wu C.C., Lo S., Hou M.F., Yuan S.S. Resistin expression in breast cancer tissue as a marker of prognosis and hormone therapy stratification. Gynecol Oncol 2012, 125:742-750.
24. Dalamaga M., Karmaniolas K., Papadavid E., Pelekanos N., Sotiropoulos G., Lekka A. Elevated serum visfatin/nicotinamide phosphoribosyl-transferase levels are associated with risk of postmenopausal breast cancer independently from adiponectin, leptin, and anthropometric and metabolic parameters. Menopause 2011, 8:1198-1204.
25. Dalamaga M., Karmaniolas K., Kontos F., Migdalis I., Dionyssiou-Asteriou A. Clinical study on the serum carcinoembryonic antigen, CA 19-9, CA 50, and alpha-fetoprotein levels in patients with myelodysplastic syndromes. Leuk Lymphoma 2006, 47:1782-1787.
26. Kassi E., Dalamaga M., Hroussalas G., Kazanis K., Merantzi G., Zachari A., et al. Adipocyte factors, high-sensitive C-reactive protein levels and lipoxidative stress products in overweight postmenopausal women with normal and impaired OGTT. Maturitas 2010, 67:72-77.
27. Duffy M.J., Evoy D., McDermott E.W. CA 15-3: uses and limitation as a biomarker for breast cancer. Clin Chim Acta 2010, 411:1869-1874.
28. Ravishankaran P., Karunanithi R. Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patients. World J Surg Oncol 2011, 9:18.
29. Papadopoulou E., Tripsianis G., Anagnostopoulos K., Tentes I., Kakolyris S., Galazios G., et al. Significance of serum tumor necrosis factor-alpha and its combination with HER-2 codon 655 polymorphism in the diagnosis and prognosis of breast cancer. Int J Biol Markers 2010, 25:126-135.
30. Nagaev I., Bokarewa M., Tarkowski A., Smith U. Human resistin is a systemic immune-derived proinflammatory cytokine targeting both leukocytes and adipocytes. PLoS One 2006, 1:e31.
31. Di Simone N., Di Nicuolo F., Sanguinetti M., Castellani R., D'Asta M., Caforio L., et al. Resistin regulates human choriocarcinoma cell invasive behaviour and endothelial cell angiogenic processes. J Endocrinol 2006, 189:691-699.
32. Maggio A.B., Wacker J., Montecucco F., Galan K., Pelli G., Mach F., et al. Serum Resistin and Inflammatory and Endothelial Activation Markers in Obese Adolescents. J Pediatr 2012, 161:1022-1027.
33. Janke J., Engeli S., Gorzelniak K., Luft F.C., Sharma A.M. Resistin gene expression in human adipocytes is not related to insulin resistance. Obes Res 2002, 10:1-5.